Latest Ratios: P/E Ratio -3.3x · EV/EBITDA N/A · ROE -94.8%. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $945M | $911M | $750M | $1.1B | $831M | $929M | $1.7B | $577M | $494M | $356M | $110M |
| Enterprise Value | $817M | $782M | $543M | $1.0B | $794M | $845M | $1.4B | $558M | $485M | $351M | $108M |
| P/E Ratio → | -3.35 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.01 | 13.50 | 13.93 | — | — | — | — | — | — | — | — |
| P/B Ratio | 5.36 | 5.23 | 1.81 | 2.65 | 1.98 | 1.83 | 2.84 | 2.64 | 3.07 | 4.45 | 1.94 |
| P/FCF | — | — | 5.61 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 5.59 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.59 | 10.07 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 4.05 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.9% | 99.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -449.9% | -449.9% | -358.5% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -412.9% | -412.9% | -322.9% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.8% | -94.8% | -42.9% | -37.3% | -29.3% | -23.3% | -21.6% | -33.3% | -50.2% | -51.8% | -39.7% |
| ROA | -37.2% | -37.2% | -28.8% | -33.7% | -27.4% | -22.1% | -20.2% | -29.8% | -43.5% | -42.8% | -35.1% |
| ROIC | -181.3% | -181.3% | -49.7% | -32.7% | -26.1% | -27.2% | -27.5% | -28.7% | -41.4% | -41.6% | -35.1% |
| ROCE | -46.6% | -46.6% | -35.3% | -39.2% | -29.6% | -23.2% | -21.7% | -34.2% | -49.4% | -48.0% | -38.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.04 | 0.04 | 0.03 | 0.01 | 0.02 | 0.04 | 0.05 | 0.09 | 0.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.50 | -0.05 | -0.09 | -0.17 | -0.51 | -0.08 | -0.05 | -0.05 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -1.55 | — | — | — | — | — | — | — | — |
| Interest Coverage | -183.11 | -183.11 | -105.22 | -97.54 | -592.19 | -314.14 | -154.06 | -116.34 | -64.83 | -40.63 | -49.16 |
Net cash position: cash ($149M) exceeds total debt ($20M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.06 | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Quick Ratio | 6.05 | 6.05 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Cash Ratio | 5.70 | 5.70 | 9.24 | 12.02 | 18.21 | 23.07 | 24.34 | 15.22 | 13.15 | 9.29 | 12.44 |
| Asset Turnover | — | 0.09 | 0.07 | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.14 | 0.14 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 68.17 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 17.8% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $86M | $73M | $67M | $66M | $53M | $42M | $35M | $23M | $19M |
Includes 30+ ratios · 18 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KURA stock.
Kura Oncology, Inc.'s current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
Kura Oncology, Inc.'s return on equity (ROE) is -94.8%. The historical average is -43.8%.
Based on historical data, Kura Oncology, Inc. is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Kura Oncology, Inc. has 99.9% gross margin and -449.9% operating margin.
Key Metrics
Top Statement Risk
Dilutive capital raise risk
Metrics are mathematically derived from official filings.
Gross Margin Artifact Masks Deep Losses
According to the latest financial statements, Kura's gross margin hovers near 100%, yet operating margin plunged to -449.9% in 2026Q2, underscoring that licensing revenue carries negligible COGS while R&D and SG&A dominate.
The near-100% gross margin is an accounting artifact of collaboration revenue, not a reflection of underlying profitability. Operating losses have deepened from -41.7% in 2024Q4 to -449.9% in 2026Q2, driven by a 70% increase in R&D spending over the period. This negative operating leverage indicates that the company's true earning power is heavily dependent on clinical milestones and future commercialization, not current operations.
Return on Capital Decays Sharply
Based on reported figures, ROIC deteriorated from -5.6% in 2024Q4 to -121.5% in 2026Q2, while ROE fell to -87.4%, reflecting a shrinking equity base and escalating losses from late-stage trials.
The return on invested capital has worsened dramatically, with ROIC dropping from -5.6% to -121.5% over six quarters. This decay is driven by both expanding losses and a declining capital base, as accumulated deficits erode equity. The negative returns are typical for a clinical-stage biotech, but the magnitude suggests that each dollar invested is generating increasingly larger losses, a trend that will persist until ziftomenib reaches commercialization or a major partnership.
Working Capital Distorted by Milestones
Per the balance sheet data, the cash conversion cycle turned sharply negative to -1,093 days in 2026Q2, driven by a DPO of 1,767 days, reflecting the timing of collaboration payments rather than operational efficiency.
The negative cash conversion cycle is a distortion caused by large deferred revenue balances and milestone-based inflows, not by efficient working capital management. DSO has been volatile, swinging from 311 days in 2025Q1 to 50 days in 2026Q2, while DPO remains elevated due to the recognition of collaboration liabilities. Investors should focus on the underlying cash burn, which is more accurately captured by operating cash flow, rather than these accounting-driven ratios.
Leverage Rises as Equity Erodes
As reported in the balance sheet, debt-to-equity surged from 0.03 in 2024Q1 to 0.39 in 2026Q2, not from new borrowing but from a collapsing equity base, signaling rising financial strain.
Total debt remained modest at $18.9M, but the debt-to-equity ratio increased tenfold as equity shrank from $505.1M to $48.4M. Interest coverage is deeply negative at -211.6, indicating that operating losses far exceed any interest expense, though the company's minimal debt service is not an immediate concern. The real leverage risk is the need for external capital to fund operations, as the equity base is insufficient to absorb further losses.
Cash Buffer Shrinks to Critical Levels
According to the latest balance sheet, cash dropped to $70.2M in 2026Q2, with a current ratio of 4.73, implying less than one quarter of runway based on the current burn rate.
The current ratio remains above 4, but this is misleading because a significant portion of current assets may be tied up in deferred revenue or other non-cash items. With quarterly operating losses around $73M, the $70.2M cash position suggests imminent financing needs. The quick ratio of 4.71 indicates that inventory is not a concern, but the rapid depletion of cash reserves warrants close monitoring of capital-raising activities.
Misapplied Metric: Gross Margin
The most commonly misapplied ratio for Kura is gross margin, which appears near 100% but obscures the true economics of a clinical-stage biotech where R&D, not COGS, drives value.
Investors may be misled by the high gross margin, interpreting it as a sign of profitability. However, this metric is irrelevant for a company with no product sales; the real measure of value creation is the progress of ziftomenib in clinical trials and the potential peak sales. A more appropriate metric is the ratio of R&D investment to clinical milestones achieved, or the cash runway relative to the expected time to regulatory approval. Gross margin should be disregarded entirely for Kura.